{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T20:00:58Z","timestamp":1759089658489},"reference-count":8,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2009,8,13]],"date-time":"2009-08-13T00:00:00Z","timestamp":1250121600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1111\/j.1600-0609.2009.01335.x","type":"journal-article","created":{"date-parts":[[2009,8,13]],"date-time":"2009-08-13T09:11:23Z","timestamp":1250154683000},"page":"611-612","source":"Crossref","is-referenced-by-count":5,"title":["Hyperleukocytotic secondary acute myeloid leukemia (AML) with sole monosomy 7 as sequela of Philadelphia\u2010chromosome positive chronic myeloid leukemia (CML)"],"prefix":"10.1111","volume":"83","author":[{"given":"Bj\u00f6rn","family":"Hackanson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anja","family":"R\u00fcckert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"L\u00fcbbert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,11,10]]},"reference":[{"key":"e_1_2_3_2_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-01-070045"},{"key":"e_1_2_3_3_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-07-2053"},{"key":"e_1_2_3_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403399"},{"key":"e_1_2_3_5_2","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1182\/blood.V110.11.300.300","article-title":"Continued low\u2010dose decitabine (DAC) is an active first\u2010line treatment in all cytogenetic subgroups of older AML patients: results of the FR00331 multicenter phase II study [abstract]","volume":"110","author":"L\u00fcbbert M","year":"2007","journal-title":"Blood"},{"key":"e_1_2_3_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404796"},{"key":"e_1_2_3_7_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-03-080630"},{"key":"e_1_2_3_8_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-017400"},{"key":"e_1_2_3_9_2","article-title":"Clinical significance of development of Philadelphia\u2010chromosome negative clones in patients with chronic myeloid leukemia treated with imatinib mesylate","volume":"90","author":"Perel JM","year":"2005","journal-title":"Haematologica"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0609.2009.01335.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1600-0609.2009.01335.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T04:04:48Z","timestamp":1697429088000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0609.2009.01335.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11,10]]},"references-count":8,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["10.1111\/j.1600-0609.2009.01335.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1600-0609.2009.01335.x","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,11,10]]}}}